Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Andreas Lazar"'
Autor:
Sven Stodtmann, Mong-Jen Chen, Lucia Siovitz, Mareike Bereswill, Andreas Lazar, Nicholas Croft, Jaroslaw Kierkus, William A Faubion, Nael M Mostafa
Publikováno v:
Journal of Crohn'scolitis. 16(10)
Background and Aims The Phase 3 study ENVISION I demonstrated efficacy and safety of adalimumab in paediatric patients with moderate to severe ulcerative colitis. The protocol-specified high-dose adalimumab regimen was numerically more efficacious th
Autor:
Felipe Rieth de Lima, Luísa Barreto Rippel, Sandy Gabrielly Radünz Machado, Aury Nunes de Moraes, Bárbara Corbellini Rovaris, Anderson Barbosa de Moura, Andreas Lazaros Chryssafidis
Publikováno v:
International Journal for Parasitology: Parasites and Wildlife, Vol 24, Iss , Pp 100956- (2024)
Southern brown-howler monkeys (Alouatta guariba clamitans) may harbor Trypanoxyuris sp., a pinworm parasite with documented fatal consequences in this species. Despite this risk, effective treatment protocols remain unclear. Therefore, the present st
Externí odkaz:
https://doaj.org/article/f09a0d7485c841eb84ee4bdde4727ac6
Autor:
Stephen B. Hanauer, Kristina Kligys, William J. Sandborn, Jean-Frederic Colombel, J Petersson, Severine Vermeire, Qian Zhou, Andreas Lazar, Walter Reinisch
Publikováno v:
Journal of Crohn's & Colitis
Background and Aims The efficacy and safety of adalimumab for induction and maintenance of clinical remission in patients with moderately to severely active ulcerative colitis were demonstrated in the ULTRA 1 and 2 clinical trials. This post-hoc, poo
Autor:
Dan Turner, Mary Venetucci, Tricia Finney-Hayward, Frank M. Ruemmele, Andreas Lazar, Nicholas M. Croft, Mareike Bereswill, Toshiaki Shimizu, Nael M. Mostafa, Subra Kugathasan, Jaroslaw Kierkus, William A. Faubion, Yuri Sanchez Gonzalez
Publikováno v:
The lancet. Gastroenterologyhepatology. 6(8)
Biologic treatment options are limited for children with ulcerative colitis. The aim of this study was to assess the safety and efficacy of adalimumab in children with moderate-to-severe ulcerative colitis.The double-blind ENVISION I study was done a
Autor:
Matheus F. L. Andreata, Leandro Afonso, Erika T. G. Niekawa, Julio M. Salomão, Kawany Roque Basso, Maria Clara D. Silva, Leonardo Cruz Alves, Stefani F. Alarcon, Maria Eugenia A. Parra, Kathlen Giovana Grzegorczyk, Andreas Lazaros Chryssafidis, Galdino Andrade
Publikováno v:
Plants, Vol 13, Iss 16, p 2246 (2024)
The increasing need for sustainable agricultural practices, combined with the demand for enhanced crop productivity, has led to a growing interest in utilizing microorganisms for biocontrol of diseases and pests, as well as for growth promotion. In B
Externí odkaz:
https://doaj.org/article/3469fb352bde4e2eb57e4262667b81b5
Autor:
Georgia Vairaktari, Alexander Schramm, Efstathia Vairaktari, Spyridoula Derka, Andreas Sakkas, Nikolaos Lefantzis, Stavroula Diamantopoulou, Antonis Vylliotis, Andreas Lazaris, Marcel Ebeling, Stavros Vassiliou
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 7, p 729 (2024)
Cutaneous squamous cell carcinoma (cSCC) is a common and increasingly prevalent form of skin cancer, posing significant health challenges. Understanding the molecular mechanisms involved in cSCC progression is crucial for developing effective treatme
Externí odkaz:
https://doaj.org/article/0d2a0103efeb4c27a63a5851a9586389
Autor:
Anne M. Robinson, Jen Fue Maa, Frank M. Ruemmele, Joel R. Rosh, Marla Dubinsky, William A. Faubion, Jeffrey S. Hyams, Andreas Lazar, Dan Turner, Gabriela Alperovich, Samantha Eichner
Publikováno v:
Journal of Crohn's & Colitis
Background and Aims Adalimumab has been shown to be more effective than placebo in healing fistulae in adults with moderately to severely active Crohn’s disease. The efficacy and safety of adalimumab in healing fistulae in children/adolescents with
Autor:
Andreas Lazar, Jeffrey S. Hyams, Yao Li, Frank M. Ruemmele, Thomas D. Walters, Robert N. Baldassano, William A. Faubion, Samantha Eichner, Johanna C. Escher, Roopal Thakkar, Anne M. Griffiths, Bidan Huang
Publikováno v:
Inflammatory Bowel Diseases, 23(6), 967-975. Oxford University Press
Growth failure is common in children with Crohn's disease. The effect of adalimumab (ADA), a fully human antitumor necrosis factor antagonist, on height velocity in pediatric patients with baseline (BL) linear growth impairment in the IMAgINE 1 trial
Autor:
Anne M. Robinson, Frank M. Ruemmele, Roopal Thakkar, Samantha Eichner, Jeffrey S. Hyams, Yao Li, Johanna C. Escher, Nattanan Reilly, Joel R. Rosh, William A. Faubion, Andreas Lazar, Marla Dubinsky
Publikováno v:
Inflammatory Bowel Diseases, 23(3), 453-460. Oxford University Press
Inflammatory Bowel Diseases
Inflammatory Bowel Diseases
Article first published online 26 January 2017. Supplemental Digital Content is Available in the Text
Background: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn's disease. Long-term efficac
Background: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn's disease. Long-term efficac
Autor:
Andreas Lazar, Ravi Shankar Prasad Singh, Roopal Thakkar, Anne M. Robinson, Yasuko Nishimura, Morio Ozawa, Kori Wallace, Nael M. Mostafa, Mamoru Watanabe, Yasuo Suzuki, Satoshi Motoya, Toshifumi Hibi
Publikováno v:
Inflammatory Intestinal Diseases. 2:228-235
Background: Dose escalation is often recommended for loss of response in anti-TNFα-treated patients with Crohn’s disease (CD). This 52-week phase 3, multicenter study investigated the efficacy and safety of escalation to adalimumab 80 mg every oth